Tax contributes apoptosis resistance to HTLV-1-infected T cells via suppression of Bid and Bim expression

Cell Death and Disease

Volumn 5, Issue 12, 2014, Pages

  Muhleisen A ^a   Giaisi, M ^a   Kohler R ^a   Krammer, P H ^a   Li Weber, M ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; DOXORUBICIN; ESTROGEN RECEPTOR; ETOPOSIDE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN BID; PUMA PROTEIN; TAX PROTEIN; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; BID PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOPROTEIN; TAX PROTEIN, HUMAN T-LYMPHOTROPHIC VIRUS 1;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; JURKAT CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; T CELL LEUKEMIA; TRANSACTIVATION; UPREGULATION; CELL LINE; GENETICS; HOST PATHOGEN INTERACTION; HUMAN T-LYMPHOTROPIC VIRUS 1; METABOLISM; PATHOPHYSIOLOGY; VIROLOGY;

HUMAN T-LYMPHOTROPIC VIRUS 1;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CELL LINE; DOWN-REGULATION; GENE PRODUCTS, TAX; HOST-PATHOGEN INTERACTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MEMBRANE PROTEINS; PROTO-ONCOGENE PROTEINS;

EID: 84927927086     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.536     Document Type: Article

References (63)

1. Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2005; 24: 5931-5937.
2. Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3: 388.
3. Taylor GP, Matsuoka M. Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene 2005; 24: 6047-6057.
4. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270-280.
5. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011; 30: 1379-1389.
6. Tsukahara T, Kannagi M, Ohashi T, Kato H, Arai M, Nunez G et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus type 1 Tax through NF-kappaB in apoptosis-resistant T-cell transfectants with Tax. J Virol 1999; 73: 7981-7987.
7. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000; 96: 275-281.
8. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C et al. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006; 107: 3933-3939.
9. Okamoto K, Fujisawa J, Reth M, Yonehara S. Human T-cell leukemia virus type-I oncoprotein Tax inhibits Fas-mediated apoptosis by inducing cellular FLIP through activation of NF-kappaB. Genes Cells 2006; 11: 177-191.
10. Swaims AY, Khani F, Zhang Y, Roberts AI, Devadas S, Shi Y et al. Immune activation induces immortalization of HTLV-1 LTR-Tax transgenic CD4+ T cells. Blood 2010; 116: 2994-3003.
11. Macaire H, Riquet A, Moncollin V, Biemont-Trescol MC, Duc Dodon M, Hermine O et al. Tax protein-induced expression of antiapoptotic Bfl-1 protein contributes to survival of human T-cell leukemia virus type 1 (HTLV-1)-infected T-cells. J Biol Chem 2012; 287: 21357-21370.
12. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA et al. The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 2000; 6: 1389-1399.
13. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727-730.
14. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2009; 27(Suppl 1): S128-S136.
15. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001; 15: 1481-1486.
16. Cartron PF, Gallenne T, Bougras G, Gautier F, Manero F, Vusio P et al. The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 2004; 16: 807-818.
17. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
18. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol 2002; 22: 3577-3589.
19. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. BID: a novel BH3 domain-only death agonist. Genes Dev 1996; 10: 2859-2869.
20. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856-859.
21. Akita K, Kawata S, Shimotohno K. p21WAF1 modulates NF-kappaB signaling and induces anti-apoptotic protein Bcl-2 in Tax-expressing rat fibroblast. Virology 2005; 332: 249-257.
22. Czabotar PE, Colman PM, Huang DC. Bax activation by Bim? Cell Death Differ 2009; 16: 1187-1191.
23. Ott M, Norberg E, Zhivotovsky B, Orrenius S. Mitochondrial targeting of tBid/Bax: a role for the TOM complex? Cell Death Differ 2009; 16: 1075-82.
24. Chlichlia K, Moldenhauer G, Daniel PT, Busslinger M, Gazzolo L, Schirrmacher V et al. Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene 1995; 10: 269-277.
25. Bleumink M, Kohler R, Giaisi M, Proksch P, Krammer PH, Li-Weber M. Rocaglamide breaks TRAIL resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP expression. Cell Death Differ 2011; 18: 362-370.
26. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and-independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004; 24: 2875-2889.
27. Xie L, Johnson RS, Freeman RS. Inhibition of NGF deprivation-induced death by low oxygen involves suppression of BIMEL and activation of HIF-1. J Cell Biol 2005; 168: 911-920.
28. Seenath MM, Roberts D, Cawthorne C, Saunders MP, Armstrong GR, O'Dwyer ST et al. Reciprocal relationship between expression of hypoxia inducible factor 1alpha (HIF-1alpha) and the pro-apoptotic protein bid in ex vivo colorectal cancer. Br J Cancer 2008; 99: 459-463.
29. Whelan KA, Caldwell SA, Shahriari KS, Jackson SR, Franchetti LD, Johannes GJ et al. Hypoxia suppression of Bim and Bmf blocks anoikis and luminal clearing during mammary morphogenesis. Mol Biol Cell 2010; 21: 3829-3837.
30. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004; 6: 33-43.
31. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23: 359-369.
32. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 2010; 28: 4177-4183.
33. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464.
34. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O et al. BID, BIM, and PUMA are essential for activation of the BAX-and BAK-dependent cell death program. Science 2010; 330: 1390-1393.
35. Fletcher JI, Huang DC. Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle 2008; 7: 39-44.
36. Deeb G, Vaughan MM, McInnis I, Ford LA, Sait SN, Starostik P et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res 2011; 35: 579-584.
37. Whelan KA, Reginato MJ. Surviving without oxygen: Hypoxia regulation of mammary morphogenesis and anoikis. Cell Cycle 2011: 10.
38. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732.
39. Peloponese JM Jr, Jeang KT. Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein. J Biol Chem 2006; 281: 8927-8938.
40. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS. BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 2002; 4: 842-849.
41. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C et al. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax. AIDS Res Hum Retroviruses 2000; 16: 1669-1675.
42. Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004; 104: 1490-1497.
43. Kfoury Y, Nasr R, Hermine O, de Théand H, Bazarbachi A. Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway. Cell Death Differ 2005: 871-877.
44. Westerberg CM, Hägglund H, Nilsson G. Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation. Cell Death Dis 2012; 3: e417.
45. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000; 157: 411-421.
46. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685.
47. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14: 191-201.
48. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7: 3598-3608.
49. Koh MY, Spivak-Kroizman T, Venturini S, Welsh S, Williams RR, Kirkpatrick DL et al. Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1alpha. Mol Cancer Ther 2008; 7: 90-100.
50. Schwartz DL, Bankson JA, Lemos R Jr., Lai SY, Thittai AK, He Y et al. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther 2010; 9: 2057-2067.
51. Minowada J, Onuma T, Moore GE. Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes. J Natl Cancer Inst 1972; 49: 891-895.
52. Seon BK, Negoro S, Barcos MP, Tebbi CK, Chervinsky D, Fukukawa T. Monoclonal antibody SN2 defining a human T cell leukemia-associated cell surface glycoprotein. J Immunol 1984; 132: 2089-2095.
53. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 1995; 7: 83-95.
54. Weiss A, Wiskocil RL, Stobo JD. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 1984; 133: 123-128.
55. Scherer WF, Syverton JT, Gey GO. Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 1953; 97: 695-710.
56. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985; 229: 563-566.
57. Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y. AT-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Gann 1981; 72: 978-981.
58. Pauwels R, De Clercq E, Desmyter J, Balzarini J, Goubau P, Herdewijn P et al. Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J Virol Methods 1987; 16: 171-185.
59. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980; 77: 7415-7419.
60. Rowe T, Dezzutti C, Guenthner PC, Lam L, Hodge T, Lairmore MD et al. Characterization of a HTLV-I-infected cell line derived from a patient with adult T-cell leukemia with stable co-expression of CD4 and CD8. Leuk Res 1995; 19: 621-628.
61. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
62. Baumann S, Fas SC, Giaisi M, Muller WW, Merling A, Gulow K et al. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1-and Ca2+-dependent apoptosis. Blood 2008; 111: 2354-2363.
63. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541-1548.